Chen Q, et al. - The potential utility of epithelial membrane protein 2 (EMP2) as a novel biomarker for circulating tumor cells (CTC) retrieval in breast cancer was assessed. For breast cancer cell spiking, researchers used PBMCs isolated from healthy donors. They used CD45-depleted PBMCs from breast cancer patients’ blood for CTC capturing. To concentrate the captured cells, they first performed cytospin centrifugation, which was followed by immunofluorescence staining with anti-CD45 mAb, anti-pan cytokeratin mAb and 4',6-Diamidino-2-phenylindole. According to findings, EMP2 enabled a better capturing of both MCF7 and MDA-MB-231 cells, vs epithelial cell adhesion molecule. In addition, EMP2 was identified as a novel biomarker, which showed the ability to capture breast cancer cells in patient blood samples.